Molecular Oncology
Volume 3, Issue 1 , Pages 77-83, February 2009

Ebselen abrogates TNFα induced pro-inflammatory response in glioblastoma

National Brain Research Centre, Manesar, Gurgaon, Haryana 122 050, India

Received 3 June 2008; received in revised form 24 September 2008; accepted 15 October 2008. published online 25 November 2008.

Abstract 

We investigated the pro-inflammatory response mediated by TNFα in glioblastoma and whether treatment with organoselenium Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]one) can affect TNFα induced inflammatory response. Exposure to TNFα increased the expression of pro-inflammatory mediator interleukin IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1) and cyclooxygenase (COX-2). Treatment with Ebselen abrogated TNFα induced increase in pro-inflammatory mediators. Ebselen not only abrogated TNFα induced enhanced invasiveness of glioma cells by down-regulating matrix metallo proteinase (MMP-9) and urokinase plasminogen (uPa) activity, but also inhibited glioma cell migration. Treatment with Ebselen also down-regulated the enhanced ROS production of TNFα treated glioma cells. In addition, Ebselen induced DNA damage repair signaling response in glioma cells both in the presence and absence of TNFα. These studies indicate that together with its known ability to sensitize glioma cell to TNFα induced apoptosis, Ebselen can overcome TNFα induced pro-inflammatory mediators to prevent a build up of a deleterious pro-inflammatory tumor microenvironment.

Keywords: Glioblastoma, TNFα, Ebselen, Pro-inflammatory cytokines

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(08)00129-4

doi:10.1016/j.molonc.2008.10.004

Molecular Oncology
Volume 3, Issue 1 , Pages 77-83, February 2009